215 related articles for article (PubMed ID: 31262667)
21. Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: a high incidence of 11q13/CCND1 and 16q23/MAF.
Takimoto M; Ogawa K; Kato Y; Saito T; Suzuki T; Irei M; Shibuya Y; Suzuki Y; Kato M; Inoue Y; Takahashi M; Sugimori H; Miura I
Int J Hematol; 2008 Apr; 87(3):260-5. PubMed ID: 18274833
[TBL] [Abstract][Full Text] [Related]
22. [Application of CD138 Immunomagnetic Sorting Myeloma Cells Combined with Fluorescence in Situ Hybridization for Detecting Cytogenetic Abnormalities of Multiple Myeloma].
Gao L; Liu Q; Shi Y; Dang H; He Q; Wang Z; Feng L; Li Y; Wang XY; Li N; Song WJ; Wang YL; Kong S; Lu J; Huang XJ; Lai YY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):807-812. PubMed ID: 28641640
[TBL] [Abstract][Full Text] [Related]
23. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J; Goyal S; Chen Z; Boise LH; Lonial S; Nooka AK; Kaufman JL
Blood Cancer J; 2019 Nov; 9(12):94. PubMed ID: 31767829
[TBL] [Abstract][Full Text] [Related]
24. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
Chan NC; Chan NP
Methods Mol Biol; 2017; 1541():295-302. PubMed ID: 27910031
[TBL] [Abstract][Full Text] [Related]
25. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions.
Chang H; Sloan S; Li D; Keith Stewart A
Br J Haematol; 2004 Nov; 127(3):280-4. PubMed ID: 15491286
[TBL] [Abstract][Full Text] [Related]
26. Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India.
Govindasamy P; Pandurangan P; Tarigopula A; Mani R; R Samuel C
Asian Pac J Cancer Prev; 2019 Jan; 20(1):235-241. PubMed ID: 30678438
[TBL] [Abstract][Full Text] [Related]
27. IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.
Mao XH; Zhuang JL; Zhao DD; Li XQ; Du X; Hao M; Xu Y; Yan YT; Liu JH; Fan HS; Sui WW; Deng SH; Li CW; Zhao JW; Yi SH; Du CX; Zou DH; Li ZJ; Zhao YZ; Zhan FH; Tai YT; Fang BJ; Song YP; Wang JX; Anderson KC; Qiu LG; An G
Eur J Haematol; 2020 Sep; 105(3):326-334. PubMed ID: 32421883
[TBL] [Abstract][Full Text] [Related]
28. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.
Rajkumar SV; Gupta V; Fonseca R; Dispenzieri A; Gonsalves WI; Larson D; Ketterling RP; Lust JA; Kyle RA; Kumar SK
Leukemia; 2013 Aug; 27(8):1738-44. PubMed ID: 23515097
[TBL] [Abstract][Full Text] [Related]
29. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
[TBL] [Abstract][Full Text] [Related]
30. [The significances of 13q14 deletion for development and prognosis of multiple myeloma].
Li Q; An G; Li CW; Xu Y; Deng SH; Liu XP; Qi JY; Wang YF; Zou DH; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):217-20. PubMed ID: 21569701
[TBL] [Abstract][Full Text] [Related]
31. Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis.
Koren-Michowitz M; Hardan I; Berghoff J; Yshoev G; Amariglio N; Rechavi G; Nagler A; Trakhtenbrot L
Cancer Lett; 2007 Oct; 255(2):307-14. PubMed ID: 17590504
[TBL] [Abstract][Full Text] [Related]
32. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
[TBL] [Abstract][Full Text] [Related]
33. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
El-Ghammaz AM; Abdelwahed E
Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
[TBL] [Abstract][Full Text] [Related]
35. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.
Harrison CJ; Mazzullo H; Cheung KL; Gerrard G; Jalali GR; Mehta A; Osier DG; Orchard KH
Br J Haematol; 2003 Mar; 120(6):944-52. PubMed ID: 12648063
[TBL] [Abstract][Full Text] [Related]
36. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma.
Murase T; Ri M; Narita T; Fujii K; Masaki A; Iida S; Inagaki H
Cancer Sci; 2019 Aug; 110(8):2600-2606. PubMed ID: 31218784
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center.
Liu Z; Zeng Q; Xiang B
Medicine (Baltimore); 2021 May; 100(18):e25834. PubMed ID: 33950994
[TBL] [Abstract][Full Text] [Related]
39. High-risk cytogenetics in multiple myeloma: Further scrutiny of deletions within the IGH gene region enhances risk stratification.
Smith SC; Althof PA; Dave BJ; Sanmann JN
Genes Chromosomes Cancer; 2020 Oct; 59(10):569-574. PubMed ID: 32447782
[TBL] [Abstract][Full Text] [Related]
40. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
Drach J; Ackermann J; Fritz E; Krömer E; Schuster R; Gisslinger H; DeSantis M; Zojer N; Fiegl M; Roka S; Schuster J; Heinz R; Ludwig H; Huber H
Blood; 1998 Aug; 92(3):802-9. PubMed ID: 9680348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
